There are more than 7,000 rare diseases affecting millions of individuals worldwide. With small patient populations, clinical trial hurdles and economic constraints, rare diseases present distinct challenges that often limit the development of viable treatments. Given these challenges, intellectual property (IP) protection provides a key value driver for companies seeking to address unmet needs of rare disease patients. This panel will bring together the IP perspectives of a venture-backed biotechnology company, a multinational pharmaceutical company and a leading academic institution, each of which is at the forefront of developing innovative medicines for rare diseases. The panel will provide stakeholders with tools for assessing the relative value of different types of IP in view of the importance of being first to market, for balancing IP protection with regulatory exclusivity to maximize value, and for understanding IP issues in leveraging partnerships and university advances.

Ability Level: All

Session ID: 21004